Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 5/20 | 1.00 |
| ▸ | TUBB | P07437 | 5/20 | 1.00 |
| ▸ | TUBA3C | P0DPH7 | 5/20 | 1.00 |
| ▸ | TUBA1B | P68363 | 5/20 | 1.00 |
| ▸ | TUBA4A | P68366 | 5/20 | 1.00 |
| ▸ | TUBB4B | P68371 | 5/20 | 1.00 |
| ▸ | TUBB3 | Q13509 | 5/20 | 1.00 |
| ▸ | TUBB2A | Q13885 | 5/20 | 1.00 |
| ▸ | TUBB8 | Q3ZCM7 | 5/20 | 1.00 |
| ▸ | TUBA3E | Q6PEY2 | 5/20 | 1.00 |
| ▸ | TUBA1A | Q71U36 | 5/20 | 1.00 |
| ▸ | TUBA1C | Q9BQE3 | 5/20 | 1.00 |
| ▸ | TUBB6 | Q9BUF5 | 5/20 | 1.00 |
| ▸ | TUBB2B | Q9BVA1 | 5/20 | 1.00 |
| ▸ | TUBB1 | Q9H4B7 | 5/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | HTR2A | P28223 | 1/20 | 0.58 |
| ▸ | HTR2C | P28335 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29227073 | 0.88 | TUBB4A (0.78) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL9185649 | 0.86 | TUBB4A (0.75) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4464142 | 0.85 | HTR2A (0.75) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL9189942 | 0.85 | TUBB4A (0.73) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL9183359 | 0.85 | TUBB4A (0.73) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL9184918 | 0.85 | TUBB1 (0.73) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL9188688 | 0.83 | TUBB4A (0.71) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL20693265 | 0.83 | TUBB4A (0.71) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL6483085 | 0.83 | CYP19A1 (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL16372691 | 0.83 | TUBB4A (0.71) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240350448-A1 | DICHLOROACETIC ACID CONJUGATING DIPHENYL ETHANE COMPOUND, AND PREPARATION METHOD AND APPLICATION THEREOF | SHANGHAI ECUSTBIOMEDICINECOMPANY LTD. (CN) | 2024-10-24 | — | — | US | disclosed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | disclosed |
| CN-114573490-B | Diaryl-2H-aziridine compounds, preparation method and application thereof | 复旦大学 | 2024-04-30 | — | — | CN | disclosed |
| CN-114573490-A | diaryl-2H-aziridines and diaryl aziridines compounds, preparation method and application thereof | 复旦大学 | 2022-06-03 | — | — | CN | disclosed |
| CN-110526805-A | A kind of fluorine substituted diphenylamine ethane derivative and preparation method and application | SHANGHAI INST TECH | 2019-12-03 | — | — | CN | disclosed |
| CN-110240539-A | A kind of fluorine substituted diphenylamine ethane compound and preparation method and application | 上海应用技术大学 | 2019-09-17 | — | — | CN | disclosed |
| US-RE45907-E1 | Functionalized stilbene derivatives as improved vascular targeting agents | OXIGENE, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| EP-2351730-B1 | ETHOXY DIPHENYL ETHANE DERIVATES, PREPARATION PROCESSES AND USES THEREOF | SHANGHAI ECUST BIOMEDICINE CO LTD (CN) | 2014-07-30 | — | — | EP | disclosed |
| CN-102245560-B | Ethoxy diphenyl ethane derivates, preparation processes and uses thereof | SHANGHAI ECUST BIOMEDICINE CO LTD | 2014-04-16 | — | — | CN | disclosed |
| US-20120046492-A1 | Ethoxy Diphenyl Ethane Derivatives, Preparation Processes and Uses Thereof | Zhejiang Wild Wind Pharmaceutical Co., Ltd. (CN) | 2012-02-23 | — | — | US | disclosed |
| WO-2006036743-A2 | HALOCOMBSTATINS AND METHODS OF SYNTHESIS THEREOF | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2006-04-06 | — | — | WO | disclosed |
| US-20060035868-A1 | Functionalized stilbene derivatives as improved vascular targeting agents | MATEON THERAPEUTICS, INC. | 2006-02-16 | — | — | US | disclosed |
| US-20050240062-A1 | Structural modification of resveratrol: Sodium resverastatin phosphate | NATIONAL INSTITUTES OF HEALTH | 2005-10-27 | — | — | US | disclosed |
| US-20050176688-A1 | Halocombstatins and methods of synthesis thereof | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA | 2005-08-11 | — | — | US | disclosed |
| EP-1438281-A2 | FUNCTIONALIZED STILBENE DERIVATIVES AS IMPROVED VASCULAR TARGETING AGENTS | Oxigene, Inc. (US) | 2004-07-21 | — | — | EP | disclosed |
| US-20030149003-A1 | Functionalized stilbene derivatives as improved vascular targeting agents | MATEON THERAPEUTICS, INC. | 2003-08-07 | — | — | US | disclosed |
| WO-2003035008-A2 | FUNCTIONALIZED STILBENE DERIVATIVES AS IMPROVED VASCULAR TARGETING AGENTS | OXIGENE, INC. (US) | 2003-05-01 | — | — | WO | disclosed |
| US-5430062-A | Combretastatin analogues; inhibition of tubulin polymerization and colchicine binding; antitumor,-mitotic and -neoplastic agents | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1995-07-04 | — | — | US | disclosed |
| EP-0641301-A1 | STILBENE DERIVATIVES AS ANTICANCER AGENTS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1995-03-08 | — | — | EP | disclosed |
| WO-1993023357-A1 | STILBENE DERIVATIVES AS ANTICANCER AGENTS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1993-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149003-A1 | Functionalized stilbene derivatives as improved vascular targeting agents | FLT1, FLT4, KDR | TUBB4A 6/4885TUBB 17/4885TUBA3C 148/4885 |
| US-20240350448-A1 | DICHLOROACETIC ACID CONJUGATING DIPHENYL ETHANE COMPOUND, AND PREPARATION METHOD AND APPLICATION THEREOF | DDT, DDC, PCCA | TUBB4A 677/4885TUBB 533/4885TUBA3C 331/4885 |
| US-20050240062-A1 | Structural modification of resveratrol: Sodium resverastatin phosphate | PI4KB, HDAC4, PIK3CA | TUBB4A 436/4885TUBB 1612/4885TUBA3C 3019/4885 |
| US-20060035868-A1 | Functionalized stilbene derivatives as improved vascular targeting agents | FLT1, FLT4, KDR | TUBB4A 6/4885TUBB 17/4885TUBA3C 148/4885 |
| US-20120046492-A1 | Ethoxy Diphenyl Ethane Derivatives, Preparation Processes and Uses Thereof | TUBB1, TUBB, TUBB3 | TUBB4A 6/4885TUBB 2/4885TUBA3C 21/4885 |
| US-20050176688-A1 | Halocombstatins and methods of synthesis thereof | TUBB3, TUBB8B, TUBB8 | TUBB4A 12/4885TUBB 6/4885TUBA3C 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.